DalsnaFinance

NeuroSense Therapeutics $NRSN

Health Care

Israel
Create a scorecard
$4.03
+0.10 (+2.41%)
As of Oct 5, 2026, 5:14 PM EDT · cached
Price history
Loading chart…

NeuroSense Therapeutics (NRSN) is trading up at $4.03 (+2.41%), as of the latest quote. It operates in the Health Care sector.

IPO: December 9, 2021 · $6.00 offering · NASDAQ · View IPO details →

NeuroSense Therapeutics net income history (FY2019–FY2025)

Net income
$0−$5.56M−$11.1MFY2019 net income: −$1.22M'19FY2020 net income: −$2.83M'20FY2021 net income: −$3.22M'21FY2022 net income: −$10.5M'22FY2023 net income: −$10.1M'23FY2024 net income: −$10.2M'24FY2025 net income: −$11.1M'25
NeuroSense Therapeutics annual financial statements
FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Operating income−$1.24M−$2.89M−$2.98M−$10.6M−$12.0M−$9.90M−$11.1M
Net income−$1.22M−$2.83M−$3.22M−$10.5M−$10.1M−$10.2M−$11.1M
EPS (diluted)—−$0.51−$0.52−$0.91−$0.74−$0.54−$0.44
Balance sheet
Cash and equivalents$895.0K$699.0K$11.1M$3.54M$2.64M$3.38M$166.0K
Total assets—$779.0K$11.4M$7.72M$3.19M$4.58M$1.03M
Total liabilities—$120.0K$2.42M$1.87M$4.94M$1.99M$2.59M
Shareholders' equity$918.0K$659.0K$10.8M$5.84M−$1.76M$2.58M−$1.56M
Cash flow
Operating cash flow−$582.0K−$695.0K−$1.54M−$7.62M−$8.35M−$10.1M−$7.67M
Capital expenditure$7.00K$9.00K$17.0K$70.0K$29.0K$3.00K$8.00K
Free cash flow−$589.0K−$704.0K−$1.56M−$7.69M−$8.38M−$10.1M−$7.68M
Dividends paid$27.0K$28.0K$29.0K$310.0K$310.0K——

From NeuroSense Therapeutics's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. Filings on SEC EDGAR →

About NeuroSense Therapeutics

Headquarters
Herzliya, Israel From SEC filings, Oct 2026

Recent News (1)

More Health Care stocks

Browse all companies →